US Drug Recall Register
Class II · Moderate risk Terminated Initiated Sep 12, 2019 (7 years ago)

Sodium Citrate 40 mg/mL

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

What was recalled

Sodium Citrate 40 mg/mL (4%) / Gentamicin 0.32 mg/mL. 30 mL vial for Intra-Catheter Use Only, Rx Only, KRS Global Biotechnology 791 Park of Commerce Blvd, Boca Raton, FL 33487. NDC 3321676603

Recalling firm
KRS Global Biotechnology, Inc
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0102-2020

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Gentamicin recalls

See all
Class II · Moderate risk Ongoing

Gentamicin Injection

Reason Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis.

Eugia US LLC NDC 55150-401-01 D-0472-2025
Class II · Moderate risk Terminated

Gentamicin Bladder 0.08mg/Ml

Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Pharmacy Innovations D-0209-2023
Class II · Moderate risk Terminated

Gentamicin Sulfate Cream USP

Reason cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Teligent Pharma, Inc. NDC 70512-036-30 D-0702-2022
Class II · Moderate risk Terminated

Gentamicin Sulfate Ointment USP 0.1%

Reason cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Teligent Pharma, Inc. NDC 52565-090-15 D-0687-2022
Class II · Moderate risk Terminated

Gentamicin Sulfate Cream USP

Reason cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Teligent Pharma, Inc. NDC 52565-085-15 D-0686-2022